Oral Semaglutide
OASIS 2
Novo Nordisk · Phase 3 · Completed · Enrollment 201
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| oral semaglutide 50 mg once daily | n/r | n/r | n/r | n/r |
| oral semaglutide placebo once daily | n/r | n/r | n/r | n/r |
Not shown
- oral semaglutide 50 mg once daily: endpoint not reported
- oral semaglutide placebo once daily: endpoint not reported